Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized open-label comparison of intravenous rhEPO-Fc versus Rexabor for maintenance treatment of anemia in hemodialysis patients with chronic kidney disease
ChiCTR2300072822Phase 3Completed
- Sponsor
- Peking University People's Hospital
- Start
- Feb 2020
- Modality
- Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rhEPO-Fc and erythropoietin in anemia of chronic kidney disease (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: Change in mean hemoglobin from baseline during weeks 21 to 28. Started Feb 2020; status: completed.
02
Drugs
rhEPO-Fcerythropoietin
03
Conditions
anemia of chronic kidney disease
Beyond the preview
Go deeper on ChiCTR2300072822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072822.